1. Home
  2. AVDL vs MNKD Comparison

AVDL vs MNKD Comparison

Compare AVDL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • MNKD
  • Stock Information
  • Founded
  • AVDL 2015
  • MNKD 1991
  • Country
  • AVDL Ireland
  • MNKD United States
  • Employees
  • AVDL N/A
  • MNKD N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • MNKD Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVDL Health Care
  • MNKD Health Care
  • Exchange
  • AVDL Nasdaq
  • MNKD Nasdaq
  • Market Cap
  • AVDL 1.5B
  • MNKD 1.7B
  • IPO Year
  • AVDL 1996
  • MNKD 2004
  • Fundamental
  • Price
  • AVDL $14.35
  • MNKD $5.72
  • Analyst Decision
  • AVDL Strong Buy
  • MNKD Strong Buy
  • Analyst Count
  • AVDL 8
  • MNKD 5
  • Target Price
  • AVDL $20.88
  • MNKD $10.80
  • AVG Volume (30 Days)
  • AVDL 1.3M
  • MNKD 3.8M
  • Earning Date
  • AVDL 11-11-2025
  • MNKD 11-06-2025
  • Dividend Yield
  • AVDL N/A
  • MNKD N/A
  • EPS Growth
  • AVDL N/A
  • MNKD 149.32
  • EPS
  • AVDL N/A
  • MNKD 0.11
  • Revenue
  • AVDL $221,075,000.00
  • MNKD $301,736,000.00
  • Revenue This Year
  • AVDL $64.56
  • MNKD $16.36
  • Revenue Next Year
  • AVDL $30.60
  • MNKD $20.34
  • P/E Ratio
  • AVDL N/A
  • MNKD $52.68
  • Revenue Growth
  • AVDL 132.35
  • MNKD 21.48
  • 52 Week Low
  • AVDL $6.38
  • MNKD $3.38
  • 52 Week High
  • AVDL $16.66
  • MNKD $7.63
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 43.90
  • MNKD 63.58
  • Support Level
  • AVDL $14.85
  • MNKD $5.33
  • Resistance Level
  • AVDL $15.58
  • MNKD $5.90
  • Average True Range (ATR)
  • AVDL 0.48
  • MNKD 0.21
  • MACD
  • AVDL -0.26
  • MNKD -0.02
  • Stochastic Oscillator
  • AVDL 12.16
  • MNKD 77.46

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Share on Social Networks: